Sarcasm, Criticism, and Social Commentary: A Speech Act Analysis of Tahilalats Digital Comics
Applied Linguistics: Innovative Approaches and Emerging Trends · 2024
DOI: 10.58989/appling.v1i2.24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Linguistics: Innovative Approaches and Emerging Trends, 2024. Verfasst von Wina Riski Rahmatika. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study examines expressive illocutionary speech acts in Mindblowon's Tahilalats comic on Instagram using a descriptive qualitative research method. The findings identify 122 instances of expressive illocutionary speech acts, which are classified into seven categories: gratitude (24 instances), criticism (116 instances), sympathy (15 instances), praise (16 instances), greetings (21 instances), blaming (9 instances), and apologies (21 instances). Criticism emerges as the most dominant speech act, reflecting the characteristic use of sarcastic humor and social satire in Tahilalats comics. In contrast, blaming is the least frequent speech act, suggesting a tendency to avoid direct confrontation. This study demonstrates that Tahilalats comics effectively employ expressive illocutionary speech acts to establish emotional connections between characters and readers.
Zitieren
APA
Rahmatika, W. R. (2024). Sarcasm, Criticism, and Social Commentary: A Speech Act Analysis of Tahilalats Digital Comics. Applied Linguistics: Innovative Approaches and Emerging Trends. https://doi.org/10.58989/appling.v1i2.24
Vancouver
Rahmatika WR. Sarcasm, Criticism, and Social Commentary: A Speech Act Analysis of Tahilalats Digital Comics. Applied Linguistics: Innovative Approaches and Emerging Trends. 2024. doi:10.58989/appling.v1i2.24
BibTeX
@article{Rahmatika2024,
author = {Rahmatika, Wina Riski},
title = {Sarcasm, Criticism, and Social Commentary: A Speech Act Analysis of Tahilalats Digital Comics},
journal = {Applied Linguistics: Innovative Approaches and Emerging Trends},
year = {2024},
doi = {10.58989/appling.v1i2.24}
}
EUVIMED